Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.
Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Alessandro Maselli CEO | NYSE Exchange | US1488061029 ISIN |
United States Country | 17,000 Employees | - Last Dividend | - Last Split | 31 Jul 2014 IPO Date |
Catalent, Inc. is a global leader in delivering innovative solutions for drug development, biologic therapeutics, and consumer health products. With its foundation dating back to 1933, Catalent prides itself on its comprehensive expertise in advancing molecules, biologics, and consumer health products from early development to full-scale production. The company operates through two main segments: Biologics, and Pharma and Consumer Health, providing a broad spectrum of services worldwide. Catalent is committed to serving the pharmaceutical, biotechnology, consumer health, animal health, medical devices, and cosmetics industries. Headquartered in Somerset, New Jersey, Catalent stands as a pivotal partner for companies in various healthcare sectors, facilitating the pathway from laboratory to market.
Biologics Segment Services:
Pharma and Consumer Health Segment Services:
Additional Services and Solutions: